落新妇甙对大鼠移植主动脉平滑肌细胞增殖的影响
摘要
目的探讨落新妇甙对大鼠移植主动脉平滑肌细胞的影响。
材料和方法成年SD大鼠30只为供体, Wistar大鼠30只为受体,随机分为2组,落新妇甙组和对照组,每组15只。落新妇甙组:于移植术后当日起采用腹腔注射注射落新妇甙,剂量为5mg/kg.d,连续7天。对照组:术后未接受落新妇甙治疗。各组大鼠于移植术后7,14,28天分批处死,每组每个时间点5只。测定Bcl-2,Bax的表达,行标本组织病理学观察和图象分析。
结果与对照组相比,落新妇甙组术后Bax升高( P < 0.05),Bcl-2无明显改变.病理观察显示:落新妇甙组术后各时间段病理损害程度均明显轻于对照组,血管平滑肌细胞增殖明显受到抑制。
结论主动脉移植术后早期应用落新妇甙可有效抑制同种大鼠移植动脉硬化,作用机制与抑制血管平滑肌细胞增殖有关。
Objective: To evaluate the effect of Astilbin treatment in rat aortic homograft smooth muscle cell.
Materials and Methods: Rat AVHs were heterotopically allografted onto abdominal aorta from SD rats (n=30) to Wistar rats (n=30). Wistar rats were divided into two groups, Control group and Astilbin group,15 rats each group.Astilbin group were treated with Astilbin(5mg/kg.d.)respectively within 1 weeks after transplantation. Control group were given no Astilbin. 5 rats were sacrificed in batches at 7、14、28 days postoperatively each group. Aortic homograft specimens were obtained for assessing Bcl-2, Bax, histological studies and image analysis.
Results: Compared with controls Bax was significantly increased in Astilbin group. Bcl-2 was no obvious change in tow groups. Histological studies showed: In each time the pathological damage in Astilbin group were significantly lighter than the control group, significantly inhibited proliferation of vascular smooth muscle cell.
Conclusion: Astilbin treatment at early stage after transplantation may inhibit arterioscleriosis in aortic allograft, the mechanism is related to inhibition of vascular smooth muscle cell proliferation.
材料和方法成年SD大鼠30只为供体, Wistar大鼠30只为受体,随机分为2组,落新妇甙组和对照组,每组15只。落新妇甙组:于移植术后当日起采用腹腔注射注射落新妇甙,剂量为5mg/kg.d,连续7天。对照组:术后未接受落新妇甙治疗。各组大鼠于移植术后7,14,28天分批处死,每组每个时间点5只。测定Bcl-2,Bax的表达,行标本组织病理学观察和图象分析。
结果与对照组相比,落新妇甙组术后Bax升高( P < 0.05),Bcl-2无明显改变.病理观察显示:落新妇甙组术后各时间段病理损害程度均明显轻于对照组,血管平滑肌细胞增殖明显受到抑制。
结论主动脉移植术后早期应用落新妇甙可有效抑制同种大鼠移植动脉硬化,作用机制与抑制血管平滑肌细胞增殖有关。
Objective: To evaluate the effect of Astilbin treatment in rat aortic homograft smooth muscle cell.
Materials and Methods: Rat AVHs were heterotopically allografted onto abdominal aorta from SD rats (n=30) to Wistar rats (n=30). Wistar rats were divided into two groups, Control group and Astilbin group,15 rats each group.Astilbin group were treated with Astilbin(5mg/kg.d.)respectively within 1 weeks after transplantation. Control group were given no Astilbin. 5 rats were sacrificed in batches at 7、14、28 days postoperatively each group. Aortic homograft specimens were obtained for assessing Bcl-2, Bax, histological studies and image analysis.
Results: Compared with controls Bax was significantly increased in Astilbin group. Bcl-2 was no obvious change in tow groups. Histological studies showed: In each time the pathological damage in Astilbin group were significantly lighter than the control group, significantly inhibited proliferation of vascular smooth muscle cell.
Conclusion: Astilbin treatment at early stage after transplantation may inhibit arterioscleriosis in aortic allograft, the mechanism is related to inhibition of vascular smooth muscle cell proliferation.
引文
1. Solez K, Benediktsson H, Cavallo T, et al. Report of the Third Banff Conference on Allograft Pathology (July 20224, 1995) on classification and lesion scoring in renal allograft pathology [J]. Transplant Proc, 1996, 28 (1):441-444
2. Susin SA , Lorenzo HK, Zamzami N , et al . Molecular characterization of mitochondrial apoptosis - inducing factor [J]. Nature, 1999, 397:441 - 446
3. Adams JM, Cory S. The Bcl - 2 protem family: arbiters of cell survival [J] .Science, 1998, 28:1322 - 1326
4. Marno I ,Brenner C ,Zamnami N ,et al . The permeability transition pore complex: a target for apoptosis regulation by caspase and Bcl - 2 - related proteins [J]. J Exp Med, 1998, 187:1261 - 1271
5. Kroemer G, Reed JC. Mitochondrial control of cell death [J]. Nature med, 2000, 6:513 - 519
6. Earnshaw WC. Apoptosis: a cellular poison cupboard [J]. Nature, 1999, 397:387 - 389
7. Marno I ,Brenner C , Zamnami N , et al . The permeability transition porecomplex: a target for apoptosis regulation by caspase and Bcl - 2– related proteins [J]. J Exp Med, 1998, 187:1261 - 1271
8. Dimmeler S, Breitschopf K,Haendeler J, Zeiher AM. Dephosphorylation targets Bcl - 2 for ubiquitin - dependent degradation: a link between the apoptosome and the proteasome pathway [J]. J Exp Med. 1999 Jun 7; 189 (11):1815.
9. Diez J , Fortuno MA , Zalba G, et al1Altered regulation of smooth muscle cell proliferation and apoptosis in small arteries of spontaneously hypertensive rats [J ]1Eur Heart J ,1998 ,19 (Supply) :29
10. ltvai ZN , M illiman CL , Korsmeyer SJ. Bcl - 2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death [J]. Cell, 1993,74 (4) : 609-619.
11.万磊,许涛,李树生.丹参预防家兔动脉粥样硬化的分子机制[J ] .现代中西医结合杂志,2006 ,15 (22) :3045 - 3049.
12.金惠民,刘俊荣,罗跃娥,等.调肝导浊中药对体外培养大鼠主动脉平滑肌细胞增殖调控的影响[J ] .天津中医药,2004 ,4 (21) :332 -334.
13. Han L K, Ninomiya H , Taniguchi M , et al . Norepinephrine augmenting lipolytic effectors f rom Astilbe thunbergii rhizomes.J Nat Prod, 1998, 61:1006-1011.
14. Motoyashiki T, Miyake M, Morita T, et al. Enhancement of the vanadate2stimulated release of lipoprotein lipase activity by astilbin from the leaves of engelhardtia chrysolepis. Biol Pharm Bull , 1998 , 21 :517-519.
15.高思海,潘铁成.落新妇甙的提取及对心肌缺血再灌注损伤的保护作用研究.中华实用中西医杂志, 2003 , 3 :1693-1694.
1. Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones. 2007 Apr-Jun; 39(2):86-93. Review.
2. PMID: 17933075 [PubMed - indexed for MEDLINE]
3. Chien KR主编.刘中民,张代富,主译,分子心脏病学[M ].北京:人民卫生出版[3] Chien S. Effect of mechanical forces on signal tansduction and gene expression in endothelium cells [J]. Hypertension, 1998 ,31 (1) :162 - 169.社, 2002, 331-352.
4. Manabe I, Nagai R. Molecular mechanisms regulating phenotypic modulation of smooth muscle cell [J]. Circ Med, 1995, 13 (2):76 - 81.
5. Kawai-Kowase K, Owens GK.Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells.Am J Physiol Cell Physiol. 2007 Jan;292(1):C59-69. Epub 2006 Sep 6. Review. PMID: 16956962 [PubMed - indexed for MEDLINE]
6. Rzucidlo EM, Martin KA, Powell RJ Regulation of vascular smooth muscle cell differentiation.J Vasc Surg. 2007 Jun;45 Suppl A:A25-32.
7. Klemm DJ ,Watson PA, FridMG, et al. CAMP response element2binding p rotein Content is a molecular determinant of smooth muscle cell p roliferation and migration [J]. J Biol Chem, 2003, 276 (49) : 46132-46141.
8. Han TH, Prywes R. Regulation role of MEF2D in serum induction of the c - jin promoter [J]. Mol Cell Biol, 2005, 15(10):2907 - 2915.
9. Michael K, Klaus M. Endothelin and restnosis [J]. Cardiovasc Res, 1998, 39(3):550 - 555.
10. Hanada M,Saito E , Kambe T , et al . Evidence for the involvement of platelet derived growth factor in the angiotensinⅡinduced growth of rat vascular smooth muscle cells[J ] . Biol Pharm Bull, 2004 ,22 (2) :137-141.
11. Mondrof UF, Geiger H, Herrero M, et al. Involvernent of the platelet derived growth factor receptor in angiotensinⅡinduced adtivation of extracellular regulated dinases 1and 2 in human mesangial cells[J ] .FEBS Lett ,2004 ,472(1) :129-132.
12. Li J ,Huang SL ,Guo ZG. Platelet derived growth factor stimulated vascular smooth muscle cell proliferation and its molecular mechanism [J]. Scta Phamacol Sin, 2000, 21 (37):340-344.
13. Pasche B. Role of TGF2beta in cancer [J]. Journal of Cellular Physiology, 2001, 186 (3):153-168.
14. Stanislaw JW, Minghao Z, Ying F, et al. Express of TGF-β1 and urokinase type plasminogen activator genes during arterial repair in the pig [J]. Cardiovascular Res, 1996, 31(1):28-33.
15. Eguchi S. Intracellular signaling of angiotensinⅡ- induced p70 S6 kinase phosphorylation at Ser (411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular Signal2regulated kinase, and Akt [J]. J Biol Chem, 1999, 274 (52):843-851.
16. Schmitt JF ,Keogh MC ,Dennehy U , et al . Tissue2selective expression of Dominant-negative proteins for the regulation of vascular smooth muscle cell proliferation [J]. Gene Ther, 1999, 6(6):1184-1191.
17. Wang X,Wang W,Li Y, et al . Mechanism of SNAP potentiating anti-Proliferative effect of calcitonin gene-related peptide in cultured vascular smooth muscle cells [J ] . J Mol Cell Cardiol, 1999, 31 (9):1599-1606.
18. Hsieh JK, Kletsas D, Clum G, et al. p53, p21 (WAF1PCIP1) and MDM involvement in the proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells [J]. Arterioscler Thromb Vasc Biol, 2006, 20(4):973-981.
19. Varenne O, Sinnaeve P, Gillijns H, et al. Percutaneous gene therapy using recombinant adenoviruses encoding human herps simplex virus thymidine kinase, Human PAI-1 and human NOS3 in balloon injured porcine coronary arteries [J]. Hum Gene Ther, 2000, 11 (9): 1329-1339.
20. Jiang C, Yang YF, Cheng SH. Fas ligand gene therapy for vascular intimal hyperplasia [J]. Curr Gene Ther, 2004, 4 (1): 33-39.
21. Rutanen J , Turunen AM, TeittinenM, et al. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism [ J ]. Gene Ther, 2005, 12 (12): 980-987.
22. Morishita R. Recent progress in gene therapy for cardiovascular disease.Circ[J], 2002, 66: 1077-1086.
23.甘卫华,陈荣华.转录因子decoy基因治疗的研究进展[ J ].国外医学儿科学分册, 2004, 31 (4) : 169-171.
1. Ross DN,Somerville J.Correction of pulmonary atresia with a homograft aortic valve[J]. Lancet, 1966,31:1446-1447
2. Barratt-Boyes BF,Roch ABG,Whitlock RML.Six year review of results of fresh and aortic valve replacement using an antibiotic sterilized homograft valve[J].Circulation,1977,55:353.
3. Brien MF,Stafford EG,Gardner MAH,et al.The viable cryopreserved allograft aortic valve[J].J Cardiac Surg,1987,2(suppl):153.
4. Park SZ, Reardon MJ. Current status of stentless aortic xenografts [J] .Current Opinion in Cardiology, 2000, 15(2):74281.
5. Dacey LJ. Pulmonary homografts: current status [J]. Current Opinion in Cardiology ,2000 ,15(2) :86-90.
6. Wolfgang K,Rene T,Michale H,et al.Aortic valve replacement with cryopreserved pulmonary allograft[J].J Cardiac Surg,1994,9:43.
7. Wilhelmi MH,Mertsching H,Wilhel M Role of inflammation in allogeneic and xenogendic heart valve degeneration : immunohistochemical evaluation of inflammatory endothelial cell activation.J Heart Valve Dis,2003,12(4):520
8. Oei FB,Welters MJ.Vaessen I M et a1.Hearl valve dysfunction resulting from cellular rejection in a novel heterotopic transplantation rat mode1.Transplant,2000,13(Suppl 1):S528
9. Plissonier D, Nocky D, Poncet P, et al. Sequential immunological targeting of chronic experimental arterial allograft. Transplant, 1995, 60:414 - 424.
10. Salomon RM, Friedman GB, Callow AD, et al. Cryopreserved aortic homografts contain viable smooth muscle cells capable of expressing translantation antigens. J Thorac Cardiovasc Surg , 1993 ,106 :1173 - 1180.
11. Castaneda AR. Cardiac surgery of the neonate and infant. Philadelphia: W.B. Saunders Company, 1994. 109 - 121.
12. Wilhelmi MH ,Mertsching H ,Wilhelmi M ,et al. Role of inflammation in allogeneic and xenogeneic heart valve degeneration : immunohistochemical evaluation of inflammatory endothelial cell activation. J Heart Valve Dis,2003 ,12 :520-526.
13. Koolbergen DR ,Hazekamp MG,de Heer E ,et al. The pathology of fresh and cryopreserved homograft heart valves: an analysis of forty explanted homograft valves. J Thorac cardiovasc Surg ,2002 ,124 :689-697
14. Oei FB, Stegmann AP, Vaessen LM, et al.Immunological aspects of fresh and cryopreserved aortic valve transplantation in rats. Ann Thorac Surg ,2001 ,71 S :379-384.
15. LégaréJ F ,Ross DB , Issekutz TB ,et al. Prevention of allograft heart valve failure in a rat model. J Thorac Cardiovasc Surg, 2001, 122:310-317.
16. Wilhelmi MH ,Mertsching H ,Wilhelmi M ,et al. Role of inflammation in allogeneic and xenogeneic heart valve degeneration : immunohistochemical evaluation of inflammatory endothelial cell activation. J Heart Valve Dis ,2003 ,12 :520-526.
17. Shaddy RE, Fuller TC, Anderson JB, et al. Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation. Ann Thorac Surg ,2004 ,77 :1734-1739.
18. Oei FB , Stegmann AP , Vaessen LM ,et al. Immunological aspects of fresh and cryopreserved aortic valve transplantation in rats. Ann Thorac Surg , 2001 ,71(5 Suppl) :S379
19. Hawkins JA, Hillman ND, Lambert LM, Immunogenicity of decellularized cryopre served allografts in pediatric cardiac surgery: comparison with standard cryopre served allografts. J Thorac Cardiovasc Surg , 2003 ,126 :247-252
20. Kim WG ,Lee WY, Mi Kim J .Tissue- engineered cellularized valve engrafts: a comparative animal study between plain acelularized engrafts and autologous endothelial cell seed edacelulariz edxenorafts.Int J Artif Organs,2004 Jun;27 ( 6) :501-508 .
21. KasimirM T,Weigel G ,S harma J ,et al .The decelulaiz endocrine heart valve matrix in tissue engineering :platelet adhesion and activation thrombaemost, 2005 Sep;94 (3):562一567.
22. Grauss RW,Hazekamp MG,van Vliet S ,et al. Decellularization of rat aortic valve allografts reduces leaflet destruction and extracellular matrix remodeling. J Thorac Cardiovasc Surg ,2003 ,126 :2003-2010
23.洪昊,董念国.组织工程心脏瓣膜的研究进展J Clin Cadiol(China) , 2006 , 22 (5) : 442-444
24.程力剑,张尔永.组织工程心脏瓣膜研究和临床应用前景1华西医学, 2006 , 21 (1) : 166-167
25.陈艰,杨长勇,于建华.同种带瓣主动脉移植应用免疫抑制治疗的实验研究中华胸心血管外科杂志,2001 ,17(4) :232
26. Legare J F, Ross DB, Issekutz TB et al. Prevention of allograft heart valve failure in a rat model. J Thorac Cardiovasc Surg , 2001 ,122 (2) :310
27.张晶,刘迎龙,谢宁.转化生长因子对同种带瓣大动脉植入后的保护作用1中华胸心血管外科杂志,2003 ,19(2) :111
28. Li Y, McCormack AM, Brand NJ et al. A strategy for inducing immune tolerance to valve endothelial cells through gene transfer. J Heart Valve Dis , 2000 , 9(3) :439
29. Brauner R , Nonoyama M, Drinkwater DC et al . Intracoronary adenovirus mediated transfer of immunosuppressive cytokine genes prolongs allograft survival. J Thorac Cardiovasc Surg , 1997 ,114(6) :923
30. Osamu A, Eiji Y, Shunsuke K et al. High level expression of viral interleukin-10 in cardiac allografts fails to prolong graft survival. Transplantation , 2002 ,74(11) :1603
31.高思海,潘铁成,杨辰垣.白细胞介素10基因转染对小鼠心脏移植排斥反应中细胞因子表达的影响J Clin Cardiol (China) , Nov 2004 ,Vol 20 , No 11
32. Penta A,Qureshi S,Redley-Smith R,et al.Patient status 10 or more years after“fresh”homograft replacement of the aortic valve[J].Circulation,1984,70(Suppl 1):182.
33. Fontan F,Choussat A,Deville C,et al.Aortic valve homofrafts insurgical treatment of complex cardiac malformations [J].J Thorac Cardiovasc Surg,1984,87:649.
34. Disumma M,Donegani E,Zattera GF,et al.Successful orthotopic transplantation of a fresh tricuspid valve homofraft in a human[J].Ann Thorac Surg,1993,56(6):1407.
35. Pomar JL,Mestres CA.Tricuspid valve replacement using a mitral homofraft technique and initial results [J].J Heart Valve dis,1993,2(2):125.
2. Susin SA , Lorenzo HK, Zamzami N , et al . Molecular characterization of mitochondrial apoptosis - inducing factor [J]. Nature, 1999, 397:441 - 446
3. Adams JM, Cory S. The Bcl - 2 protem family: arbiters of cell survival [J] .Science, 1998, 28:1322 - 1326
4. Marno I ,Brenner C ,Zamnami N ,et al . The permeability transition pore complex: a target for apoptosis regulation by caspase and Bcl - 2 - related proteins [J]. J Exp Med, 1998, 187:1261 - 1271
5. Kroemer G, Reed JC. Mitochondrial control of cell death [J]. Nature med, 2000, 6:513 - 519
6. Earnshaw WC. Apoptosis: a cellular poison cupboard [J]. Nature, 1999, 397:387 - 389
7. Marno I ,Brenner C , Zamnami N , et al . The permeability transition porecomplex: a target for apoptosis regulation by caspase and Bcl - 2– related proteins [J]. J Exp Med, 1998, 187:1261 - 1271
8. Dimmeler S, Breitschopf K,Haendeler J, Zeiher AM. Dephosphorylation targets Bcl - 2 for ubiquitin - dependent degradation: a link between the apoptosome and the proteasome pathway [J]. J Exp Med. 1999 Jun 7; 189 (11):1815.
9. Diez J , Fortuno MA , Zalba G, et al1Altered regulation of smooth muscle cell proliferation and apoptosis in small arteries of spontaneously hypertensive rats [J ]1Eur Heart J ,1998 ,19 (Supply) :29
10. ltvai ZN , M illiman CL , Korsmeyer SJ. Bcl - 2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death [J]. Cell, 1993,74 (4) : 609-619.
11.万磊,许涛,李树生.丹参预防家兔动脉粥样硬化的分子机制[J ] .现代中西医结合杂志,2006 ,15 (22) :3045 - 3049.
12.金惠民,刘俊荣,罗跃娥,等.调肝导浊中药对体外培养大鼠主动脉平滑肌细胞增殖调控的影响[J ] .天津中医药,2004 ,4 (21) :332 -334.
13. Han L K, Ninomiya H , Taniguchi M , et al . Norepinephrine augmenting lipolytic effectors f rom Astilbe thunbergii rhizomes.J Nat Prod, 1998, 61:1006-1011.
14. Motoyashiki T, Miyake M, Morita T, et al. Enhancement of the vanadate2stimulated release of lipoprotein lipase activity by astilbin from the leaves of engelhardtia chrysolepis. Biol Pharm Bull , 1998 , 21 :517-519.
15.高思海,潘铁成.落新妇甙的提取及对心肌缺血再灌注损伤的保护作用研究.中华实用中西医杂志, 2003 , 3 :1693-1694.
1. Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones. 2007 Apr-Jun; 39(2):86-93. Review.
2. PMID: 17933075 [PubMed - indexed for MEDLINE]
3. Chien KR主编.刘中民,张代富,主译,分子心脏病学[M ].北京:人民卫生出版[3] Chien S. Effect of mechanical forces on signal tansduction and gene expression in endothelium cells [J]. Hypertension, 1998 ,31 (1) :162 - 169.社, 2002, 331-352.
4. Manabe I, Nagai R. Molecular mechanisms regulating phenotypic modulation of smooth muscle cell [J]. Circ Med, 1995, 13 (2):76 - 81.
5. Kawai-Kowase K, Owens GK.Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells.Am J Physiol Cell Physiol. 2007 Jan;292(1):C59-69. Epub 2006 Sep 6. Review. PMID: 16956962 [PubMed - indexed for MEDLINE]
6. Rzucidlo EM, Martin KA, Powell RJ Regulation of vascular smooth muscle cell differentiation.J Vasc Surg. 2007 Jun;45 Suppl A:A25-32.
7. Klemm DJ ,Watson PA, FridMG, et al. CAMP response element2binding p rotein Content is a molecular determinant of smooth muscle cell p roliferation and migration [J]. J Biol Chem, 2003, 276 (49) : 46132-46141.
8. Han TH, Prywes R. Regulation role of MEF2D in serum induction of the c - jin promoter [J]. Mol Cell Biol, 2005, 15(10):2907 - 2915.
9. Michael K, Klaus M. Endothelin and restnosis [J]. Cardiovasc Res, 1998, 39(3):550 - 555.
10. Hanada M,Saito E , Kambe T , et al . Evidence for the involvement of platelet derived growth factor in the angiotensinⅡinduced growth of rat vascular smooth muscle cells[J ] . Biol Pharm Bull, 2004 ,22 (2) :137-141.
11. Mondrof UF, Geiger H, Herrero M, et al. Involvernent of the platelet derived growth factor receptor in angiotensinⅡinduced adtivation of extracellular regulated dinases 1and 2 in human mesangial cells[J ] .FEBS Lett ,2004 ,472(1) :129-132.
12. Li J ,Huang SL ,Guo ZG. Platelet derived growth factor stimulated vascular smooth muscle cell proliferation and its molecular mechanism [J]. Scta Phamacol Sin, 2000, 21 (37):340-344.
13. Pasche B. Role of TGF2beta in cancer [J]. Journal of Cellular Physiology, 2001, 186 (3):153-168.
14. Stanislaw JW, Minghao Z, Ying F, et al. Express of TGF-β1 and urokinase type plasminogen activator genes during arterial repair in the pig [J]. Cardiovascular Res, 1996, 31(1):28-33.
15. Eguchi S. Intracellular signaling of angiotensinⅡ- induced p70 S6 kinase phosphorylation at Ser (411) in vascular smooth muscle cells. Possible requirement of epidermal growth factor receptor, Ras, extracellular Signal2regulated kinase, and Akt [J]. J Biol Chem, 1999, 274 (52):843-851.
16. Schmitt JF ,Keogh MC ,Dennehy U , et al . Tissue2selective expression of Dominant-negative proteins for the regulation of vascular smooth muscle cell proliferation [J]. Gene Ther, 1999, 6(6):1184-1191.
17. Wang X,Wang W,Li Y, et al . Mechanism of SNAP potentiating anti-Proliferative effect of calcitonin gene-related peptide in cultured vascular smooth muscle cells [J ] . J Mol Cell Cardiol, 1999, 31 (9):1599-1606.
18. Hsieh JK, Kletsas D, Clum G, et al. p53, p21 (WAF1PCIP1) and MDM involvement in the proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells [J]. Arterioscler Thromb Vasc Biol, 2006, 20(4):973-981.
19. Varenne O, Sinnaeve P, Gillijns H, et al. Percutaneous gene therapy using recombinant adenoviruses encoding human herps simplex virus thymidine kinase, Human PAI-1 and human NOS3 in balloon injured porcine coronary arteries [J]. Hum Gene Ther, 2000, 11 (9): 1329-1339.
20. Jiang C, Yang YF, Cheng SH. Fas ligand gene therapy for vascular intimal hyperplasia [J]. Curr Gene Ther, 2004, 4 (1): 33-39.
21. Rutanen J , Turunen AM, TeittinenM, et al. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism [ J ]. Gene Ther, 2005, 12 (12): 980-987.
22. Morishita R. Recent progress in gene therapy for cardiovascular disease.Circ[J], 2002, 66: 1077-1086.
23.甘卫华,陈荣华.转录因子decoy基因治疗的研究进展[ J ].国外医学儿科学分册, 2004, 31 (4) : 169-171.
1. Ross DN,Somerville J.Correction of pulmonary atresia with a homograft aortic valve[J]. Lancet, 1966,31:1446-1447
2. Barratt-Boyes BF,Roch ABG,Whitlock RML.Six year review of results of fresh and aortic valve replacement using an antibiotic sterilized homograft valve[J].Circulation,1977,55:353.
3. Brien MF,Stafford EG,Gardner MAH,et al.The viable cryopreserved allograft aortic valve[J].J Cardiac Surg,1987,2(suppl):153.
4. Park SZ, Reardon MJ. Current status of stentless aortic xenografts [J] .Current Opinion in Cardiology, 2000, 15(2):74281.
5. Dacey LJ. Pulmonary homografts: current status [J]. Current Opinion in Cardiology ,2000 ,15(2) :86-90.
6. Wolfgang K,Rene T,Michale H,et al.Aortic valve replacement with cryopreserved pulmonary allograft[J].J Cardiac Surg,1994,9:43.
7. Wilhelmi MH,Mertsching H,Wilhel M Role of inflammation in allogeneic and xenogendic heart valve degeneration : immunohistochemical evaluation of inflammatory endothelial cell activation.J Heart Valve Dis,2003,12(4):520
8. Oei FB,Welters MJ.Vaessen I M et a1.Hearl valve dysfunction resulting from cellular rejection in a novel heterotopic transplantation rat mode1.Transplant,2000,13(Suppl 1):S528
9. Plissonier D, Nocky D, Poncet P, et al. Sequential immunological targeting of chronic experimental arterial allograft. Transplant, 1995, 60:414 - 424.
10. Salomon RM, Friedman GB, Callow AD, et al. Cryopreserved aortic homografts contain viable smooth muscle cells capable of expressing translantation antigens. J Thorac Cardiovasc Surg , 1993 ,106 :1173 - 1180.
11. Castaneda AR. Cardiac surgery of the neonate and infant. Philadelphia: W.B. Saunders Company, 1994. 109 - 121.
12. Wilhelmi MH ,Mertsching H ,Wilhelmi M ,et al. Role of inflammation in allogeneic and xenogeneic heart valve degeneration : immunohistochemical evaluation of inflammatory endothelial cell activation. J Heart Valve Dis,2003 ,12 :520-526.
13. Koolbergen DR ,Hazekamp MG,de Heer E ,et al. The pathology of fresh and cryopreserved homograft heart valves: an analysis of forty explanted homograft valves. J Thorac cardiovasc Surg ,2002 ,124 :689-697
14. Oei FB, Stegmann AP, Vaessen LM, et al.Immunological aspects of fresh and cryopreserved aortic valve transplantation in rats. Ann Thorac Surg ,2001 ,71 S :379-384.
15. LégaréJ F ,Ross DB , Issekutz TB ,et al. Prevention of allograft heart valve failure in a rat model. J Thorac Cardiovasc Surg, 2001, 122:310-317.
16. Wilhelmi MH ,Mertsching H ,Wilhelmi M ,et al. Role of inflammation in allogeneic and xenogeneic heart valve degeneration : immunohistochemical evaluation of inflammatory endothelial cell activation. J Heart Valve Dis ,2003 ,12 :520-526.
17. Shaddy RE, Fuller TC, Anderson JB, et al. Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation. Ann Thorac Surg ,2004 ,77 :1734-1739.
18. Oei FB , Stegmann AP , Vaessen LM ,et al. Immunological aspects of fresh and cryopreserved aortic valve transplantation in rats. Ann Thorac Surg , 2001 ,71(5 Suppl) :S379
19. Hawkins JA, Hillman ND, Lambert LM, Immunogenicity of decellularized cryopre served allografts in pediatric cardiac surgery: comparison with standard cryopre served allografts. J Thorac Cardiovasc Surg , 2003 ,126 :247-252
20. Kim WG ,Lee WY, Mi Kim J .Tissue- engineered cellularized valve engrafts: a comparative animal study between plain acelularized engrafts and autologous endothelial cell seed edacelulariz edxenorafts.Int J Artif Organs,2004 Jun;27 ( 6) :501-508 .
21. KasimirM T,Weigel G ,S harma J ,et al .The decelulaiz endocrine heart valve matrix in tissue engineering :platelet adhesion and activation thrombaemost, 2005 Sep;94 (3):562一567.
22. Grauss RW,Hazekamp MG,van Vliet S ,et al. Decellularization of rat aortic valve allografts reduces leaflet destruction and extracellular matrix remodeling. J Thorac Cardiovasc Surg ,2003 ,126 :2003-2010
23.洪昊,董念国.组织工程心脏瓣膜的研究进展J Clin Cadiol(China) , 2006 , 22 (5) : 442-444
24.程力剑,张尔永.组织工程心脏瓣膜研究和临床应用前景1华西医学, 2006 , 21 (1) : 166-167
25.陈艰,杨长勇,于建华.同种带瓣主动脉移植应用免疫抑制治疗的实验研究中华胸心血管外科杂志,2001 ,17(4) :232
26. Legare J F, Ross DB, Issekutz TB et al. Prevention of allograft heart valve failure in a rat model. J Thorac Cardiovasc Surg , 2001 ,122 (2) :310
27.张晶,刘迎龙,谢宁.转化生长因子对同种带瓣大动脉植入后的保护作用1中华胸心血管外科杂志,2003 ,19(2) :111
28. Li Y, McCormack AM, Brand NJ et al. A strategy for inducing immune tolerance to valve endothelial cells through gene transfer. J Heart Valve Dis , 2000 , 9(3) :439
29. Brauner R , Nonoyama M, Drinkwater DC et al . Intracoronary adenovirus mediated transfer of immunosuppressive cytokine genes prolongs allograft survival. J Thorac Cardiovasc Surg , 1997 ,114(6) :923
30. Osamu A, Eiji Y, Shunsuke K et al. High level expression of viral interleukin-10 in cardiac allografts fails to prolong graft survival. Transplantation , 2002 ,74(11) :1603
31.高思海,潘铁成,杨辰垣.白细胞介素10基因转染对小鼠心脏移植排斥反应中细胞因子表达的影响J Clin Cardiol (China) , Nov 2004 ,Vol 20 , No 11
32. Penta A,Qureshi S,Redley-Smith R,et al.Patient status 10 or more years after“fresh”homograft replacement of the aortic valve[J].Circulation,1984,70(Suppl 1):182.
33. Fontan F,Choussat A,Deville C,et al.Aortic valve homofrafts insurgical treatment of complex cardiac malformations [J].J Thorac Cardiovasc Surg,1984,87:649.
34. Disumma M,Donegani E,Zattera GF,et al.Successful orthotopic transplantation of a fresh tricuspid valve homofraft in a human[J].Ann Thorac Surg,1993,56(6):1407.
35. Pomar JL,Mestres CA.Tricuspid valve replacement using a mitral homofraft technique and initial results [J].J Heart Valve dis,1993,2(2):125.